Laboratorios Farmaceuticos ROVI SA
LSE:0ILL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (38.8), the stock would be worth €90.01 (15% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 33.8 | €78.3 |
0%
|
| 3-Year Average | 38.8 | €90.01 |
+15%
|
| 5-Year Average | 34.7 | €80.54 |
+3%
|
| Industry Average | 34.1 | €79.15 |
+1%
|
| Country Average | 18.6 | €43.08 |
-45%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| ES |
|
Laboratorios Farmaceuticos ROVI SA
LSE:0ILL
|
4B EUR | 33.8 | 28.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 140.4 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 29.1 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 35.6 | 28.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 24.8 | 15 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 19.5 | 20.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 43.8 | 11.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 21.8 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 11.6 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13 |
| Median | 18.6 |
| 70th Percentile | 28.2 |
| Max | 1 712.4 |
Other Multiples
Laboratorios Farmaceuticos ROVI SA
Glance View
Laboratorios Farmacéuticos ROVI SA has carved a niche for itself in the pharmaceutical industry through its focus on researching, developing, manufacturing, and marketing a broad range of small molecule drugs and specialized products. Founded in Spain, ROVI has channeled its efforts towards creating innovative solutions in the healthcare sector, with heparin-based products emerging as a cornerstone of its portfolio. The company's operational model is built on vertical integration, allowing it to control the entire lifecycle of its offerings, from production to commercialization. This approach not only ensures quality and compliance with stringent regulatory standards but also enables ROVI to adapt nimbly to market demands and leverage its proprietary science to secure a competitive edge. The revenue streams of ROVI are diversified across its proprietary products, contract manufacturing services, and its portfolio of licensed products. A significant portion of revenue stems from its commitment to injectable drug products like Bemiparin, a low molecular weight heparin, which has found a foothold in various international markets. Moreover, ROVI capitalizes on partnerships and alliances with major pharmaceutical giants, augmenting its contract manufacturing capabilities and tapping into more extensive distribution networks. Not resting on its laurels, ROVI invests heavily in research and development to fortify its pipeline with innovative formulations, thus ensuring sustained growth and a resilient positioning in the global pharmaceutical landscape. This blend of strategic partnerships, internal innovation, and market-responsive production underscores ROVI's business model and revenue generation prowess.